GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

It has been tough sledding for fans of dividend stocks lately, but the latest economic news could help to smooth out the ride. Long-term bond yields have tumbled as a result, which should be good news ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting caught out.

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Shalby Advanced Technologies Inc., USA, a step down subsidiary of the Company has received U.S. Food and Drug Administration ...